Search results
Results from the WOW.Com Content Network
Tamoxifen, sold under the brand name Nolvadex among others, is a selective estrogen receptor modulator used to prevent breast cancer in women and men. [13] It is also being studied for other types of cancer. [13] It has been used for Albright syndrome. [14] Tamoxifen is typically taken daily by mouth for five years for breast cancer. [14]
Museum of Mexican Medicine. In Mexico, the sixteenth century Badianus Manuscript described medicinal plants available in Central America. [8] Dr. Erick Estrada Lugo, Researcher-Professor in Phytotechnics at the State of Mexico's Chapingo Autonomous University, told the National Autonomous University of Mexico's digital magazine that “at least 90% of the population uses medicinal plants ...
Rising food prices over recent years have been linked with social unrest around the world, including rioting in Bangladesh and Mexico, [43] and the Arab Spring. [44] In 2013, Overseas Development Institute researchers showed that rice has more than doubled in price since 2000, rising by 120% in real terms. This was as a result of shifts in ...
In a 1970 clinical trial, tamoxifen, which went by the name Nolvadex, was given to 60 breast cancer patients. This anti-estrogen drug had significantly shrunk the tumors while causing minimal side effects. [6] In 1988, she published an article on the history of the development of Tamoxifen. [7] Richardson was named on several patents. [8]
A nonsteroidal estrogen is an estrogen with a nonsteroidal chemical structure. [1] The most well-known example is the stilbestrol estrogen diethylstilbestrol (DES). [1] [2] Although nonsteroidal estrogens formerly had an important place in medicine, they have gradually fallen out of favor following the discovery of toxicities associated with high-dose DES starting in the early 1970s, and are ...
The WHO Model List of Essential Medicines (aka Essential Medicines List or EML [1]), published by the World Health Organization (WHO), contains the medications considered to be most effective and safe to meet the most important needs in a health system. [2]
One of the largest breast cancer prevention studies ever, [2] it included 22,000 women in 400 medical centers in the United States and Canada. [3] [4] [5]The study concluded that raloxifene caused fewer side-effects and less endometrial cancer than tamoxifen.
Sivifene (A-007) was initially thought to be a SERM due to its structural similarity to tamoxifen but it was subsequently found not to bind to the estrogen receptor (ER). [8] Tesmilifene (DPPE; YMB-1002, BMS-217380-01) is also structurally related to tamoxifen but similarly does not bind to the ER and is not a SERM. [9] [10]